Haruki Kume
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Patients with end-stage renal disease (ESRD) are at increased risk of acquired cystic kidney disease (ACKD) and renal tumors, but the molecular basis of such disorders remains elusive. In this study, we performed spatial immunogenomic analyses on 268 specimens from 43 patients with ACKD and associated tumors. The molecular landscape of ESRD-associated tumors is different from that of sporadic renal cell carcinoma. Single-cell and spatial analyses have shown that ACKD is under an inflammatory environment and that the renal cysts in ACKD are derived from proximal tubular cells that have survived the destructive effects of inflammation. Interestingly, we revealed that cysts are formed by clonal expansion and that paracrine activation of the MET tyrosine kinase pathway by the surrounding environment nurtures cysts. Collectively, our results identify the oncogenic mechanisms of ESRD-associated renal tumors and will pave the way for improving the prognosis of patients with ESRD. Significance: We elucidated the molecular basis of renal cancer arising in patients with ESRD and show that the inflammatory environment of ESRD gives rise to field cancerization.
Year:
2025
Introduction A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)‐ related genes. poly ADP‐ribose polymerase (PARP) inhibitors have been approved for metastatic castration‐resistant prostate cancer (mCRPC) with mutations in the BRCA1/2 gene. For other HRR‐related genes, there is insufficient evidence to determine whether PARP inhibitors are effective or not. Case Presentation The patient was a 59‐year‐old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the RAD54L gene, and the expert panel recommended administration of niraparib by patient‐proposed healthcare services. Therefore, the patient was enrolled in the BELIEVE Trial and started on niraparib, which showed a marked decrease in PSA and a reduction in metastatic lesions. However, PSA subsequently began to rise and metastatic lesions were enlarged, so treatment was discontinued at 25 weeks. Conclusion Niraparib was effective for mCRPC with RAD54L gene mutation. Trial Registration The prospective trial of patient‐proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104)
Year:
2025
Introduction Docetaxel is a key treatment for castration‐resistant prostate cancer and is administered with prednisolone, which increases the risk of steroid‐induced diabetes. Its myelosuppressive effect also increases vulnerability to febrile neutropenia. Metformin is widely used for glycemic control; however, elderly cancer patients are particularly susceptible to metformin‐associated lactic acidosis, necessitating careful management of sick‐day and febrile neutropenia during chemotherapy. Case Presentation We report a 70‐year‐old male with castration‐resistant prostate cancer and diabetes mellitus who developed febrile neutropenia on Day 5 following docetaxel initiation. He progressed to shock with severe metabolic acidosis on Day 7 and died despite intensive care, including continuous renal replacement therapy. A retrospective review revealed continued metformin use despite prodromal fatigue and loss of appetite, likely due to impaired judgment. Conclusion This case may have involved septic shock, but metformin likely worsened the lactic acidosis. It highlights the need for sick‐day education and monitoring in elderly cancer patients.
Year:
2025
Introduction We describe a case in which robot‐assisted radical ureterectomy was performed for residual ureteral recurrence in a postoperative patient with renal pelvis cancer. Case presentation A 75‐year‐old woman underwent laparoscopic radical nephroureterectomy for left renal pelvic cancer at another hospital. During follow‐up, a papillary tumor was found in the bladder on cystoscopy, and a continuous tumor was found in the residual ureter on computed tomography. Robot‐assisted radical ureterectomy was performed in combination with transurethral resection of bladder tumors. To avoid urine spillage, bladder cuff excision was performed using a mechanical suture device while monitoring the interior of the bladder. Conclusion We developed a new technique for remnant ureteral resection using cystoscopy and a vascular stapler to prevent urine dissemination and cancer seeding.
Year:
2024
Introduction Pelvic arteriovenous malformations are rare in male patients. We present a case of pelvic arteriovenous malformation involving the seminal vesicle. Case presentation A 58‐year‐old man was diagnosed with pelvic arteriovenous malformation that involved the left seminal vesicle by angiography. The patient underwent three embolization procedures and made favorable progress after the embolizations. Conclusion Herein, we report a rare case of pelvic arteriovenous malformation involving the seminal vesicle treated by embolizations with good outcome.
Year:
2024
Introduction Patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome have high risks of uterine and cutaneous leiomyomas and renal cell carcinoma (RCC), which are caused by germline mutation of the fumarate hydratase (FH) gene. RCC lesions are mostly high‐grade tumors with a poor prognosis. Case presentation A 37‐year‐old man who had previously undergone treatment for a left RCC was referred to our hospital with a diagnosis of right RCC. Robot‐assisted partial nephrectomy was performed, and the pathological diagnosis revealed fumarate hydratase (FH)‐deficient RCC. The left RCC, which was originally diagnosed as mucinous tubular and spindle cell carcinoma, was reviewed and diagnosed as FH‐deficient RCC. The patient's father and uncle both died of RCC, and the father's tumor was also immunohistochemically proven to be FH‐deficient RCC. Conclusion HLRCC‐related RCC should be considered in a differential diagnosis of young patients with a family history of RCC.
Year:
2024
Introduction Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone marrow remains unclear. Case presentation We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium‐223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression‐free survival for 17 months after the initial diagnosis. Conclusion These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow.
Year:
2023
Collaborators (3)
Yuta Yamada
Associate Professor
University of Tokyo
Hiroyoshi Nishikawa
-
Tetsuo Ushiku
-
Make your next move.
Prepare your application
Review drafts before you send them.